RxDoctor Payments Data

Katherine Bivona, MD

Family Medicine · Jasper, ALNPI 1255482832

Payments from drug & device makers

$6,529in general payments, 2019–2025

Across 456 payments — averaging $14.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$844
  • Amgen$527
  • Johnson & Johnson$440
  • Pfizer$384
  • Takeda Pharmaceuticals U.S.A., Inc.$199
  • plus $2K from 43 others

What the payments were for

  • Food & beverage$6,529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,529 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$76,728
Medicare patients
502
Services billed
4,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide92$123,873
OzempicSemaglutide67$99,256
EliquisApixaban63$60,258
MyrbetriqMirabegron67$42,436
JardianceEmpagliflozin25$34,783
XareltoRivaroxaban43$32,662
FarxigaDapagliflozin Propanediol30$22,770
Janumet XrSitagliptin Phos/Metformin Hcl26$22,200
LinzessLinaclotide33$22,156
JanuviaSitagliptin Phosphate19$21,712
BriviactBrivaracetam12$16,946
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,176
Lansoprazole31$9,120
Aripiprazole19$7,700
Breo ElliptaFluticasone/Vilanterol11$7,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$55$123,87392 claims
Novo NordiskOzempic$844$99,25667 claims
PfizerEliquis, Premarin$384$63,79078 claims
MerckJanumet Xr, Januvia, Dulera$28$50,73762 claims
Astellas Pharma US IncMyrbetriq$139$42,43667 claims
Boehringer IngelheimJardiance$75$34,78325 claims
Johnson & JohnsonXarelto$440$32,66243 claims
AbbVieLinzess, Synthroid$2,012$28,011112 claims
AstraZenecaFarxiga$85$22,77030 claims
GSKTrelegy Ellipta, Breo Ellipta$187$21,85925 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$199$4,16311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Jasper

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →